Medivation Inc. (MDVN) Given a $64.00 Price Target at Leerink Swann

Henrietta Brewer
August 12, 2016

Medivation, Inc. had its "buy" rating reiterated by analysts at Canaccord Genuity. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Quotient Investors added MDVN to its portfolio by purchasing 38,025 company shares during the most recent quarter which is valued at $2,341,199. Hartford Investment Management Co. purchased a new stake in Medivation during the second quarter valued at $219,000. Daiwa Securities Group Inc. now owns 4,100 shares of the biopharmaceutical company's stock valued at $247,000 after buying an additional 700 shares during the last quarter. Ameriprise Financial Inc. now owns 531,992 shares of the biopharmaceutical company's stock worth $25,716,000 after buying an additional 12,300 shares in the last quarter.

05/05/2016 - Medivation, Inc. had its "buy" rating reiterated by analysts at Maxim Group. BlackRock Advisors LLC boosted its stake in Medivation by 3.3% in the fourth quarter.

Medivation Inc closed down -0.07 points or -0.11% at $63.18 with 10,67,796 shares getting traded on Monday. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 1.89% where SMA50 and SMA200 are 4.57% and 33.15% respectively. The Market Capitalization of the company stands at 10.51 Billion. Medivation has a 52-week low of $26.41 and a 52-week high of $65.92.

Medivation (NASDAQ:MDVN) last posted its quarterly earnings data on Tuesday, August 9th. Analyst had a consensus of $-0.20.

Medivation reaffirmed its 2016 earnings guidance of between $1.30 per share and $1.40 per share, above consensus estimates of $1.26 per share. During the same quarter in the previous year, the business posted $0.58 EPS.

Medivation's hormonal agent drug Xtandi saw its sales grow 11% year-over-year to $330.3 million due to an increase in underlying demand, the company said in a statement.

Recently analysts working for numerous investment brokerages have updated their research report ratings and price targets on shares of Medivation, Inc. The stock was sold at an average price of $60.42, for a total transaction of $155,762.76. JMP Securities cut shares of Medivation from an "outperform" rating to a "market perform" rating in a research note on Wednesday. According to these analysts, the Low Revenue Estimate for Medivation, 202250 and the High Revenue Estimate is 238850.

Newman noted, "On its call, Medivation announced Xtandi sales of ~$330M (missing $338M consensus slightly), but more important for the long-term growth story of the drug was the record mean usage duration reached during Q2, now up to 9 months".

Medivation, Inc. (NASDAQ:MDVN) reported its last earnings on Aug 09 AMC (BMO = before market open, AMC= after market close). Stifel Nicolaus raised their price objective on Medivation from $52.00 to $66.00 and gave the company a "buy" rating in a research report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock.

Medivation, a biopharmaceutical company. The Firm is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. "In addition, we anticipate a very exciting second half of 2016 for XTANDI as we prepare commercially for the October 22 PDUFA date for a potential USA label amendment to include head-to-head data of enzalutamide versus bicalutamide".

Other reports by iNewsToday